Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
The Prostaglandin E1 Analog Misoprostol Reduces Symptoms and Microvascular Arteriovenous Shunting in Erythromelalgia - A Double-Blind, Crossover, Placebo-Compared Study
2004 (engelsk)Inngår i: Journal of Investigative Dermatology Volume 122, Issue 3, Page 587-593, Mar 2004Artikkel i tidsskrift (Fagfellevurdert)
Abstract [en]

Based on previous experience with parenteral prostanoids, we studied the effect of misoprostol treatment, an orally administered prostaglandin E1 analog, in patients with erythromelalgia. Treatment with placebo was followed by treatment with misoprostol (0.40.8 mg per d), both for 6 wk. The patients (n=21) and a study nurse who administered the trial were blinded. The endpoints were change in pain and need for cooling and global assessment of the treatment. Following central body heat provocation, global skin perfusion, capillary morphology, and change in pain were also recorded before and after each treatment period. Results were compared with data from healthy control subjects (n=11) that did not undergo treatment. Clinical safety and tolerability evaluation included physical examinations, clinical laboratory tests, and monitoring of adverse events. All clinical outcome measures were signifcantly better after treatment with misoprostol (p<0.01) as compared with placebo treatment and after a 3- mo follow-up without treatment. The heat-induced increase in global perfusion after misoprostol treatment was similar to the control group and signiÞcantly lower when compared with baseline (p<0.01) and placebo treatment (p<0.05), respectively. This study demonstrates that misoprostol is clinically superior to placebo in patients with erythromelalgia. The results of the perfusion studies may imply that the mechanism of action of the beneÞcial effect of misoprostol is reduced microvascular arteriovenous shunting in affected skin

sted, utgiver, år, opplag, sider
2004.
Emneord [en]
arteriovenous shunting, clinical trial, microcirculation, prostanoids, video microscopy, laser doppler imaging
Identifikatorer
URN: urn:nbn:se:kau:diva-24700OAI: oai:DiVA.org:kau-24700DiVA, id: diva2:598470
Tilgjengelig fra: 2013-01-22 Laget: 2013-01-22 Sist oppdatert: 2014-10-28

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

http://dx.doi.org/10.1111/j.0022-202X.2004.22339.xhttp://kau.diva-portal.org/smash/get/diva2:128368/FULLTEXT01

Personposter BETA

Asker, Claes

Søk i DiVA

Av forfatter/redaktør
Asker, Claes

Søk utenfor DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric

urn-nbn
Totalt: 159 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf